X0609 4 2026-04-16 0002096997 Kailera Therapeutics, Inc. KLRA 0001628880 Pagan Douglas W. false C/O KAILERA THERAPEUTICS, INC. 180 THIRD AVENUE, 4TH FLOOR WALTHAM MA 02451 false true false false Chief Financial Officer false Stock Option (right to buy) 16 2026-04-16 4 A false 100000 0 A 2036-04-16 Common Stock 100000 100000 D Stock Option (right to buy) 16 2026-04-16 4 A false 100000 0 A 2036-04-16 Common Stock 100000 100000 D The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date. The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date. /s/ John Mei, Attorney-in-fact 2026-04-20